NCT00123942View on ClinicalTrials.gov

Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease

PHASE1TerminatedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

April 30, 2004

Conditions

Lymphoproliferative Disorders

Interventions

DRUG

MEDI-507

Trial Locations (1)

20892

National Cancer Institute/National Institutes of Health, Bethesda

Sponsors

Lead Sponsor

All Listed Sponsors

lead

MedImmune LLC

INDUSTRY